HRP20191895T4 - Adam6 miševi - Google Patents

Adam6 miševi Download PDF

Info

Publication number
HRP20191895T4
HRP20191895T4 HRP20191895TT HRP20191895T HRP20191895T4 HR P20191895 T4 HRP20191895 T4 HR P20191895T4 HR P20191895T T HRP20191895T T HR P20191895TT HR P20191895 T HRP20191895 T HR P20191895T HR P20191895 T4 HRP20191895 T4 HR P20191895T4
Authority
HR
Croatia
Prior art keywords
mouse
modification
heavy chain
immunoglobulin heavy
murine
Prior art date
Application number
HRP20191895TT
Other languages
English (en)
Inventor
Lynn Macdonald
Sean Stevens
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191895(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20191895T1 publication Critical patent/HRP20191895T1/hr
Publication of HRP20191895T4 publication Critical patent/HRP20191895T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (4)

1. Postupak za modificiranje lokusa teškog lanca imunoglobulina miša, koji obuhvaća: (a) izvođenje prve modifikacije lokusa teškog lanca imunoglobulina miša, a prva modifikacija se sastoji od smještanja jednog ili više humanih imunoglobulinskih VH, DH, i JH genskih segmenta ili zamjene jedne ili više sekvenci u lokusu teškog lanca imunoglobulina miša sa jednim ili više humanih imunoglobulinskih VH, DH, i JH genskih segmenata, gdje prva modifikacija eliminira mišju ekspresiju ADAM6 iz endogenog Adam6 alela tako da muški miš koji ima prvu modifikaciju ispoljava smanjenu plodnost; i (b) izvođenje druge modifikacije na mišu da bi se dodala sekvenca nukleinskih kiselina koja doprinosi funkcionalnosti mišje ADAM6 aktivnosti kod muškog miša, gdje nukleinska kiselinska sekvenca kodira mišji ADAM6a protein ili ortolog, homolog, ili njegov funkcionalni fragment, i mišji ADAM6b protein ili ortolog, homolog, ili njegov funkcionalni fragment, gdje spomenuta druga modifikacija je napravljena tako da je nukleinska sekvenca okružena ushodno, nizhodno, ili ushodno ili nizhodno sa nukleinskom kiselinskom sekvencom koja kodira humani imunoglobulinski varijabilni genski segment spomenutog modificiranog endogenog mišjeg imunoglobulinskog lokusa teškog lanca, poželjno gdje prva i druga modifikacija su izvedene simultano.
2. Postupak prema zahtjevu 1, gdje je miš mužjak ili gdje je miš ženka.
3. Postupak prema bilo kojem od zahtjeva 1-2, gdje prva modifikacija obuhvaća brisanje svih ili dijla varijabilnih genskih segmenta teškog lanca imunoglobulina miša.
4. Izolirana pluripotentna, inducirana pluripotentna ili totipotentna stanica ili izolirano tkivo iz miša dobiveno postupkom prema bilo kojem od zahtjeva 1-3.
HRP20191895TT 2011-02-25 2012-02-24 Adam6 miševi HRP20191895T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP12192727.1A EP2578688B2 (en) 2011-02-25 2012-02-24 ADAM6 mice

Publications (2)

Publication Number Publication Date
HRP20191895T1 HRP20191895T1 (hr) 2020-01-10
HRP20191895T4 true HRP20191895T4 (hr) 2023-05-12

Family

ID=45998616

Family Applications (5)

Application Number Title Priority Date Filing Date
HRP20191895TT HRP20191895T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20230526TT HRP20230526T1 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20192311TT HRP20192311T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20150262AT HRP20150262T1 (hr) 2011-02-25 2015-03-09 Miševi sa adam6
HRP20200294TT HRP20200294T1 (hr) 2011-02-25 2020-02-21 Miševi s adam6

Family Applications After (4)

Application Number Title Priority Date Filing Date
HRP20230526TT HRP20230526T1 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20192311TT HRP20192311T4 (hr) 2011-02-25 2012-02-24 Adam6 miševi
HRP20150262AT HRP20150262T1 (hr) 2011-02-25 2015-03-09 Miševi sa adam6
HRP20200294TT HRP20200294T1 (hr) 2011-02-25 2020-02-21 Miševi s adam6

Country Status (32)

Country Link
US (12) US8642835B2 (hr)
EP (7) EP4067496B1 (hr)
JP (7) JP2014507137A (hr)
KR (1) KR101387377B1 (hr)
CN (2) CN105861548B (hr)
AU (5) AU2012243291B2 (hr)
BR (1) BR112013021771B1 (hr)
CA (1) CA2820824A1 (hr)
CY (5) CY1116301T1 (hr)
DE (5) DE12716101T1 (hr)
DK (6) DK2738259T3 (hr)
ES (6) ES2758974T5 (hr)
FI (3) FI2578688T4 (hr)
HK (2) HK1174490A1 (hr)
HR (5) HRP20191895T4 (hr)
HU (5) HUE047687T2 (hr)
IL (4) IL226727A (hr)
IN (1) IN2013CN07629A (hr)
LT (4) LT2738258T (hr)
ME (3) ME03732B (hr)
MX (2) MX343009B (hr)
MY (1) MY172713A (hr)
NZ (2) NZ731926A (hr)
PL (5) PL4067496T3 (hr)
PT (5) PT2738258T (hr)
RS (5) RS59413B2 (hr)
RU (2) RU2582261C2 (hr)
SG (4) SG10201913160QA (hr)
SI (5) SI2550363T1 (hr)
SM (1) SMT201500061B (hr)
WO (1) WO2012141798A1 (hr)
ZA (1) ZA201305998B (hr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
EP3272770B1 (en) 2004-07-22 2023-12-20 Erasmus University Medical Center Rotterdam Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP3028564B2 (en) 2009-07-08 2024-01-24 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
DK2738259T3 (da) 2011-02-25 2020-02-17 Regeneron Pharma ADAM6-mus
CA2841376C (en) 2011-07-05 2023-02-28 Duke University N-terminal deleted gp120 immunogens
PT3572517T (pt) * 2011-08-05 2021-06-23 Regeneron Pharma Murganhos da cadeia leve universal humanizada
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
CA2846322A1 (en) * 2011-09-19 2013-03-28 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US10092638B2 (en) 2011-10-03 2018-10-09 Duke University GP120 immunogens and methods inducing neutralizing antibodies to human immunodeficiency virus
DK2627773T3 (en) 2011-10-17 2017-10-02 Regeneron Pharma MOUSE WITH LIMITED IMMUNOGLOBULIN HEAVY CHAIN
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
TR201903439T4 (tr) * 2011-12-20 2019-04-22 Regeneron Pharma İnsanlaştırılmış hafif zincirli fareler.
SG11201404477YA (en) * 2012-02-01 2014-08-28 Regeneron Pharma HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS
BR112014022853A2 (pt) 2012-03-16 2017-07-18 Regeneron Pharma animal não humano, locus de cadeia pesada de imunoglobulina geneticamente modificado em uma linhagem germinal de um animal não humano, e, método de produzir um animal não humano
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102459666B1 (ko) 2012-03-16 2022-10-27 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
JP6185978B2 (ja) 2012-03-16 2017-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒスチジン操作された軽鎖抗体およびこれを作製するための遺伝子改変された非ヒト動物
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
KR20200126007A (ko) 2012-04-20 2020-11-05 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
RS62121B1 (sr) * 2012-06-12 2021-08-31 Regeneron Pharma Humanizovane nehumane životinje sa ograničenim lokusima imunoglobulinskog teškog lanca
MX357061B (es) 2013-02-06 2018-06-25 Regeneron Pharma Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
DK2840892T3 (en) * 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
EP3841876A1 (en) * 2013-03-14 2021-06-30 Erasmus University Medical Center Rotterdam Transgenic mouse for antibody production
WO2014141192A1 (en) * 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) * 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN107072184A (zh) 2014-09-19 2017-08-18 瑞泽恩制药公司 嵌合抗原受体
WO2016149678A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
US20170247436A1 (en) 2016-02-16 2017-08-31 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
KR102628909B1 (ko) * 2016-05-20 2024-01-25 리제너론 파마슈티칼스 인코포레이티드 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
SG10201914014XA (en) 2016-06-03 2020-03-30 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
AU2018281280A1 (en) 2017-06-07 2020-01-16 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
JP7430636B2 (ja) 2017-12-05 2024-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
KR20210004994A (ko) 2018-03-26 2021-01-13 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
JP7477462B2 (ja) 2018-05-17 2024-05-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ６３抗体、コンジュゲート、及び、それらの使用
US12102070B2 (en) 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
CN113430207A (zh) 2018-06-14 2021-09-24 瑞泽恩制药公司 在免疫球蛋白重链编码序列中具有dh-dh重排能力的非人动物
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH A HUMANIZED IMMUNOGLOBULIN LOCUS
CA3127153A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
BR112021023683A2 (pt) 2019-06-05 2022-02-01 Regeneron Pharma Roedor e camundongo geneticamente modificado, embrião de roedor, célula b do roedor ou camundongo geneticamente modificado, hibridoma, população de células b, célula-tronco embrionária, célula de mamífero, métodos de produção de um anticorpo, de uma cadeia pesada, de um domínio variável, de uma coleção de domínios variáveis, de uma cadeia leve, de uma sequência nucleotídica, de um roedor geneticamente modificado e de células es, de geração de um domínio variável e in vitro para gerar uma célula recombinante de roedor, e, vetor de direcionamento
EP3785536B1 (en) * 2019-08-28 2022-01-26 Trianni, Inc. Adam6 knockin mice
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
JP2023529846A (ja) 2020-06-02 2023-07-12 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
JP2024501286A (ja) 2020-12-23 2024-01-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
BR112023011689A2 (pt) 2020-12-23 2023-10-31 Regeneron Pharma Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero
KR20230171454A (ko) 2021-04-20 2023-12-20 리제너론 파마슈티칼스 인코포레이티드 아르테민에 대한 인간 항체 및 이의 사용 방법
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0671951A4 (en) * 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
AU5043200A (en) * 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1970448A1 (en) 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
CA2583750C (en) 2004-10-19 2015-11-24 Regeneron Pharmaceuticals, Inc. Methods for generating a rodent having a genetic modification
ATE416465T1 (de) 2005-06-30 2008-12-15 Borealis Tech Oy Überzug-schicht für energie- oder kommunikationskabel
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
RS52176B (en) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
DK2379727T3 (en) * 2008-12-18 2017-01-16 Univ Erasmus Med Ct Rotterdam NON-HUMAN TRANSGENE ANIMALS EXPRESSING HUMANIZED ANTIBODIES AND USE THEREOF
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
EP3028564B2 (en) * 2009-07-08 2024-01-24 Kymab Limited Animal models and therapeutic molecules
EP3504964A1 (en) 2009-12-10 2019-07-03 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
RS59001B1 (sr) 2010-02-08 2019-08-30 Regeneron Pharma Miš sa zajedničkim lakim lancem
EP2582230A1 (en) * 2010-06-17 2013-04-24 Kymab Limited Animal models and therapeutic molecules
DK2738259T3 (da) 2011-02-25 2020-02-17 Regeneron Pharma ADAM6-mus
PT3572517T (pt) 2011-08-05 2021-06-23 Regeneron Pharma Murganhos da cadeia leve universal humanizada
DK2627773T3 (en) 2011-10-17 2017-10-02 Regeneron Pharma MOUSE WITH LIMITED IMMUNOGLOBULIN HEAVY CHAIN
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
TR201903439T4 (tr) 2011-12-20 2019-04-22 Regeneron Pharma İnsanlaştırılmış hafif zincirli fareler.

Also Published As

Publication number Publication date
EP2550363A1 (en) 2013-01-30
LT4067496T (lt) 2023-06-12
EP2578688B1 (en) 2019-07-24
DE12192727T1 (de) 2013-07-11
EP2813573B1 (en) 2020-04-22
US20210105984A1 (en) 2021-04-15
PT4067496T (pt) 2023-06-07
DK4067496T3 (da) 2023-06-26
PL4067496T3 (pl) 2023-07-31
SG192933A1 (en) 2013-09-30
US20150210776A1 (en) 2015-07-30
DK4067496T5 (da) 2024-07-22
ME03732B (me) 2021-01-20
DK2738258T3 (da) 2019-12-16
RS59413B2 (sr) 2023-06-30
US8697940B2 (en) 2014-04-15
US8642835B2 (en) 2014-02-04
EP2738259A2 (en) 2014-06-04
NZ703609A (en) 2016-04-29
US10577430B2 (en) 2020-03-03
US20180362663A1 (en) 2018-12-20
CY1122205T1 (el) 2020-11-25
US9932408B2 (en) 2018-04-03
AU2012243291A1 (en) 2013-05-09
NZ731926A (en) 2021-07-30
CN103429746A (zh) 2013-12-04
CN103429746B (zh) 2016-05-11
IL273986A (en) 2020-05-31
CA2820824A1 (en) 2012-10-18
BR112013021771A2 (pt) 2017-07-04
EP2578688A1 (en) 2013-04-10
SI2738258T2 (sl) 2023-05-31
DK2738259T3 (da) 2020-02-17
ES2805364T3 (es) 2021-02-11
CN105861548A (zh) 2016-08-17
MX2013009649A (es) 2013-09-26
EP2738258A2 (en) 2014-06-04
RU2013125717A (ru) 2014-12-10
PT2738259T (pt) 2020-02-18
RS59661B2 (sr) 2023-06-30
HRP20191895T1 (hr) 2020-01-10
AU2017251802A1 (en) 2017-11-16
CY1126091T1 (el) 2023-11-15
US20180346598A1 (en) 2018-12-06
KR20130116375A (ko) 2013-10-23
PL2550363T3 (pl) 2015-05-29
KR101387377B1 (ko) 2014-04-21
EP2738259A3 (en) 2014-07-30
CY1122820T1 (el) 2021-05-05
RS59661B1 (sr) 2020-01-31
DE14176593T1 (de) 2015-03-05
SI4067496T1 (sl) 2023-07-31
JP2014110814A (ja) 2014-06-19
SI2738258T1 (sl) 2020-01-31
FI2738258T4 (fi) 2023-05-05
CY1122459T1 (el) 2021-01-27
US20210105985A1 (en) 2021-04-15
SI2738259T1 (sl) 2020-06-30
FI4067496T3 (fi) 2023-05-24
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
PL2738258T3 (pl) 2020-08-24
HK1201292A1 (en) 2015-08-28
DK2578688T3 (da) 2019-10-28
ES2770424T3 (es) 2020-07-01
MX343009B (es) 2016-10-21
JP2015107131A (ja) 2015-06-11
AU2012243291B2 (en) 2015-07-09
ES2748832T3 (es) 2020-03-18
ES2758974T5 (es) 2023-06-08
SI2578688T2 (sl) 2023-05-31
US10072095B2 (en) 2018-09-11
RU2582261C2 (ru) 2016-04-20
NZ776770A (en) 2023-03-31
HRP20200294T1 (hr) 2020-05-29
AU2020201279A1 (en) 2020-03-12
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
IL261243A (en) 2018-10-31
WO2012141798A1 (en) 2012-10-18
IL261243B (en) 2019-08-29
DK2738258T1 (da) 2014-11-24
EP4067496A1 (en) 2022-10-05
RU2016109443A (ru) 2018-11-26
PL2738259T3 (pl) 2020-08-24
JP2016135143A (ja) 2016-07-28
IL226727A (en) 2016-08-31
IL273986B (en) 2021-04-29
US20140213773A1 (en) 2014-07-31
JP2018143250A (ja) 2018-09-20
JP2019187446A (ja) 2019-10-31
US20240306617A1 (en) 2024-09-19
HUE047687T2 (hu) 2020-05-28
EP2813573A1 (en) 2014-12-17
US20150201589A1 (en) 2015-07-23
MX2020009714A (es) 2020-10-07
RS59413B1 (sr) 2019-11-29
SG10201913155QA (en) 2020-02-27
MY172713A (en) 2019-12-11
US20180346599A1 (en) 2018-12-06
EP2738258B2 (en) 2023-02-01
NZ718688A (en) 2017-07-28
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
DE14154918T1 (de) 2014-08-21
RU2016109443A3 (hr) 2019-07-24
ES2532487T3 (es) 2015-03-27
AU2015238806A1 (en) 2015-10-29
US20120322108A1 (en) 2012-12-20
HRP20150262T1 (hr) 2015-04-10
SMT201500061B (it) 2015-05-05
HRP20230526T1 (hr) 2023-09-01
JP5866127B2 (ja) 2016-02-17
DK2738259T1 (da) 2014-11-24
EP3744850A1 (en) 2020-12-02
EP2550363B1 (en) 2014-12-10
HUE046746T2 (hu) 2020-03-30
IL268671B (en) 2020-05-31
DK2550363T3 (en) 2015-03-23
RS59929B1 (sr) 2020-03-31
PL2578688T3 (pl) 2020-05-18
PT2738258T (pt) 2019-12-10
JP2014507137A (ja) 2014-03-27
LT2738259T (lt) 2020-03-10
JP2022071051A (ja) 2022-05-13
SG10201913160QA (en) 2020-03-30
US20130254911A1 (en) 2013-09-26
HRP20192311T4 (hr) 2023-05-12
ES2946169T3 (es) 2023-07-13
HRP20192311T1 (hr) 2020-03-20
AU2022206806A1 (en) 2022-08-18
US10694725B2 (en) 2020-06-30
RS53880B1 (en) 2015-08-31
EP2738258B1 (en) 2019-09-25
PT2550363E (pt) 2015-03-16
US20180345760A1 (en) 2018-12-06
LT2738258T (lt) 2020-01-10
LT2578688T (lt) 2019-11-11
BR112013021771B1 (pt) 2022-11-16
PL2578688T5 (pl) 2023-05-29
CN105861548B (zh) 2020-01-10
HUE024534T2 (hu) 2016-01-28
ZA201305998B (en) 2016-07-27
DK2813573T1 (da) 2015-01-12
DK2578688T1 (da) 2014-11-24
NZ612643A (en) 2015-06-26
SI2578688T1 (sl) 2019-11-29
CY1116301T1 (el) 2017-02-08
ME03537B (hr) 2020-04-20
EP2738258A3 (en) 2014-09-24
RU2722373C2 (ru) 2020-05-29
DE14154967T1 (de) 2014-08-28
RS64280B1 (sr) 2023-07-31
DE12716101T1 (de) 2013-05-08
IN2013CN07629A (hr) 2015-08-07
ME02106B (me) 2015-10-20
DK2738258T4 (da) 2023-05-08
US10905108B2 (en) 2021-02-02
EP2578688B2 (en) 2023-02-08
HK1174490A1 (en) 2013-06-14
ES2748832T5 (es) 2023-06-08
HUE062552T2 (hu) 2023-11-28
DK2578688T4 (da) 2023-05-08
SG10201405135RA (en) 2014-10-30
EP2738259B1 (en) 2019-11-27
EP4067496B1 (en) 2023-03-29
IL268671A (en) 2019-10-31
US9944716B2 (en) 2018-04-17
US10905109B2 (en) 2021-02-02
FI2578688T4 (fi) 2023-05-05

Similar Documents

Publication Publication Date Title
HRP20191895T4 (hr) Adam6 miševi
MX2015012539A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
MY185881A (en) Non-human animals with modified immunoglobulin heavy chain sequences
BR112016021572A2 (pt) Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
CO2018004056A2 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
RS54367B1 (en) MUSIC WITH COMMON LIGHT CHAIN
RS54891B1 (sr) Miševi koji ispoljavaju laki lanac sa ljudskim lambda promenljivim regionom i mišjim konstantnim regionom
EP4269430A3 (en) Non-human animals having a humanized signal-regulatory protein gene
MX2021010416A (es) Moleculas fc biespecificas.
BR112016015424A2 (pt) planta transgênica; polinucleotídeo recombinante; vetor de expressão expressável em plantas; método para a produção de uma planta transformada tendo fotossíntese aprimorada; e proteína quimérica
JP2017514496A5 (hr)
CL2013002068A1 (es) Linea celular de ratón con genes inactivados nav1.7 global viable; metodo para generar ratón con dichos genes inactivados; hibridoma.
EP4345164A3 (en) Genetic engineering of non-human animals for the production of chimeric antibodies
AR078516A1 (es) Moleculas de union a dll-4 (ligando 4 de tipo delta)
BR112019000923A2 (pt) métodos e composições para expressão gênica em plantas
AR120698A1 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CO2017001724A2 (es) Anticuerpos anti-vasa y métodos de producción de los mismos
GB2458419A (en) Vector for expressing NC protein of HIV and method for producing NC protein using the same
BR112015031236A2 (pt) Produção de proteína em plantas
AR088321A1 (es) Gen codificador de citocromo p450 y su uso
DK2029751T3 (da) Inducerbart eksprimeringssystem baseret på plantevirus
AR109237A1 (es) Anticuerpos contra ip-10 y sus usos
TH166794A (th) สัตว์ที่ไม่ใช่มนุษย์ที่เป็นแบบฮิมแมไนซ์ที่มีโลคัสที่จำกัดของสายหนักของอิมมูโนโกลบูลิน
TH131553A (th) โปรโมเตอร์เพิ่มการแสดงออกของยีนในไซยาโนแบคทีเรีย
AR097922A1 (es) Exotoxina a de pseudomonas modificada